Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14247553 | 0.93 | MAPT (0.67) | MAPTPOLBPKMTDP1LMNA | |
| SCHEMBL4039191 | 0.90 | MAPT (0.66) | MAPTPOLBPKMTDP1LMNA | |
| SCHEMBL17678159 | 0.89 | MAPT (0.52) | MAPTPKMMAPK1ALDH1A1RAB9A | |
| SCHEMBL5341510 | 0.85 | CYP2C19 (0.62) | MAPTPOLBPKMTDP1LMNA | |
| SCHEMBL22456073 | 0.85 | MAPT (0.67) | MAPTPOLBPKMTDP1LMNA | |
| SCHEMBL8564086 | 0.85 | MAPT (0.61) | MAPTPOLBPKMTDP1LMNA | |
| SCHEMBL4240340 | 0.82 | MAPT (0.58) | MAPTPOLBPKMTDP1LMNA | |
| SCHEMBL22455941 | 0.82 | MAPT (0.61) | MAPTPOLBPKMTDP1LMNA | |
| SCHEMBL737318 | 0.82 | MEN1 (0.62) | MAPTPOLBPKMTDP1LMNA | |
| SCHEMBL17678243 | 0.81 | HRH3 (0.55) | MAPTPOLBPKMMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
| CN-107106561-A | Heparan sulfate biosynthesis inhibitor for treating disease | 生物马林药物股份有限公司 | 2017-08-29 | — | — | CN | disclosed |
| EP-3204009-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9650358-B2 | Pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| WO-2016057834-A9 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016057834-A9 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016057834-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057834-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | MAPT 3263/4885POLB 1821/4885PKM 1561/4885 |
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK6 | MAPT 2993/4885POLB 928/4885PKM 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.